1. Academic Validation
  2. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas

Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas

  • J Invest Dermatol. 2006 Oct;126(10):2302-7. doi: 10.1038/sj.jid.5700475.
Giovanni Ponti 1 Lorena Losi Monica Pedroni Emanuela Lucci-Cordisco Carmela Di Gregorio Giovanni Pellacani Stefania Seidenari
Affiliations

Affiliation

  • 1 Department of Internal Medicine, Division of Dermatology, University of Modena and Reggio Emilia, Modena, Italy. [email protected]
Abstract

Hereditary non-polyposis colorectal Cancer (HNPCC) is an autosomal-dominant disorder characterized by predisposition to colorectal Cancer and extracolonic malignancies, frequent multiple primary tumors in the same patient, and early age of Cancer onset. A main clinical variant of Lynch syndrome, Muir-Torre syndrome (MTS) is characterized by the association between one or more visceral malignancies, with at least one sebaceous skin tumor or keratoacanthoma. In our study, we have screened a cohort of 538 HNPCC patients, related to 57 HNPCC families, to detect sebaceous skin tumors and keratoacanthomas and the role of mismatch repair (MMR) genes, MLH1, MSH2, and MSH6, in their pathogenesis. Among the 57 HNPCC families, we have identified four MTS families and one suspected MTS family, in which sebaceous carcinoma was found in one HNPCC mutation carrier subject who did not show visceral malignancy. In four of these families, linked to two MLH1 mutations and to two MSH2 mutations, biomolecular characterization showed concordance among immunohistochemistry analysis and gene mutations. The evidences of our investigations show that MLH1 and MSH2 gene mutations have an equivalent etiopathological role both for Lynch syndrome and for MTS; hence, we propose a broadened clinical criteria for definition of Lynch syndrome that will include sebaceous adenoma, carcinoma, and keratoacanthoma.

Figures